TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.5nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.70nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.60nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.80nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.30nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.80nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.10nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.40nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.60nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.90nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.20nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.60nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.80nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.80nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.30nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.90nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.70nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.80nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.80nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 9.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 12nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 12nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 12nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 15nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 21nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 23nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 34nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 42nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 88nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 110nMAssay Description:MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 140nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetIsoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a)(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 280nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair